Bellevue Asset Management, LLC Mirati Therapeutics, Inc. Transaction History

Bellevue Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$75.82 - $150.97 $227 - $452	-3 Reduced 16.67%	15 $1,000
Q4 2021 Feb 03, 2022	SELL	$132.01 - $190.29 $132 - $190	-1 Reduced 5.26%	18 $3,000
Q2 2021 Aug 09, 2021	BUY	$144.0 - $179.73 $1,152 - $1,437	8 Added 72.73%	19 $3,000
Q1 2021 May 12, 2021	BUY	$158.92 - $221.61 $1,748 - $2,437	11 New	11 $2,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Bellevue Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bellevue Asset Management, LLC with notifications on news.